IMPORTANT SAFETY INFORMATION: PROHEART 6 should be used in healthy dogs. Do not administer to sick, debilitated, underweight dogs or dogs that have a history of weight loss. Prior to administration, PROHEART 6 certified veterinarians should continue to assess patient health through a medical history, physical examination and if deemed appropriate, diagnostic testing. Continue to use caution when administering PROHEART 6 concurrently with vaccinations. Adverse events, including anaphylaxis, have been reported following the concomitant use of PROHEART 6 and vaccines. In some cases, anaphylactic reactions have resulted in death. Use with caution in dogs with pre-existing or uncontrolled allergic disease (food allergy, atopy or flea allergy dermatitis). Dogs receiving PROHEART 6 should be tested for existing heartworms as per the product label. In people, avoid PROHEART 6 contact with eyes. If contact with the eyes occurs, rinse thoroughly with water for 15 minutes and seek medical attention immediately. PROHEART 6 is available only to veterinarians through a restricted distribution program. Only certified veterinarians and staff can administer it. See Brief Summary of full Prescribing Information on page XX.
Confidence
I believe ProHeart 6 will eliminate concerns about compliance for six months at a time while keeping patients protected against heartworm year-round and while also providing an opportunity to monitor patients' health during the 2nd dose visit.

Invitation to neutral
Let’s review some information about ProHeart 6…

It’s the customer’s decision
…so you can decide whether ProHeart 6 will benefit your practice, your canine patients, and their pet owners.

ProHeart 6 is the only injectable heartworm product that ensures compliance.

And now - the in-use shelf life of ProHeart 6 is 56 days.

This update gives your customers twice the time to use each reconstituted vial of ProHeart 6.

What This Means: More Time, Less Pressure
• The in-use shelf life of reconstituted vials of ProHeart 6 is now 56 days.
• Your customers have twice the time to use each reconstituted vial of ProHeart 6.
• ProHeart 6 formulation is unchanged. FDA-CVM approved this label change as effective and appropriate after reviewing the necessary Zoetis in-use stability studies.

To learn more, visit ProHeart6DVM.com.

Sound Byte
CHECK-OFF & ECHO NOTES

Check-Off (Qualify)
Identify if a Zoetis representative has been in recently:
Doctor, are you familiar with ProHeart 6, the only heartworm disease preventative that provides 6 months’ protection in 1 injection?
If YES, confirm and discuss benefits of ProHeart 6. If NO, detail as the primary contact
ProHeart® 6 (moxidectin)

Sustained Release Injectable for Dogs

**DESCRIPTION**
ProHeart® 6 (moxidectin) Sustained Release Injectable consists of two separate vials: One vial contains 10% moxidectin sterile microspheres and the second vial contains a specifically formulated sterile vehicle for constitution with the microspheres. No other diluent should be used for reconstitution of the microspheres. Each mL of constituted drug product contains 3.4 mg moxidectin, 3.1% glyceryl tristearate, 2.4% hydroxpropyl methylcellulose, 0.87% sodium chloride, 0.17% methylparaben, 0.02% propylparaben and 0.001% butylated hydroxytoluene. Hydrochloric acid is used to adjust pH. Moxidectin is a semi-synthetic methoxime derivative of nemadectin, a fermentation product of Streptomyces cyanogriseus subsp. noncyanogenus. Moxidectin is a pentalcycly-16-membered lactone macrolide. Moxidectin has activity resulting in paralysis and death of affected parasites. The stage of the canine heartworm affected at the time of treatment will determine the efficacy of ProHeart® 6. The larval and adult stages of the canine hookworms, Ancylostoma caninum and Uncinaria stenocephala, are susceptible. Following injection with ProHeart® 6, peak moxidectin blood levels will be observed approximately 7-14 days after treatment. At least six months dosing interval, residual drug concentrations are negligible. Accordingly, little or no drug accumulation is expected to occur with repeated administrations.

**INDICATIONS**
ProHeart® 6 is indicated for use in dogs six months of age and older for the prevention of heartworm disease caused by *Dirofilaria immitis*. ProHeart® 6 is indicated for the treatment of existing larval and adult hookworms (*Ancylostoma caninum* and *Uncinaria stenocephala*). ProHeart® 6 is indicated for the treatment of existing or adult heartworm infections caused by *D. immitis*.

**DOSEAGE AND ADMINISTRATION**
Owners should be given the Client Information Sheet for ProHeart® 6 to read before the drug is administered and should be advised to observe their dogs for potential drug toxicity described in the sheet.

**Frequency of treatment:** ProHeart® 6 prevents infection by *D. immitis* for six months of age and older dogs administered within one month of the dog’s first exposure to mosquitos. Follow-up treatments may be given every six months if the dog has continued exposure to mosquitoes and if the dog continues to be healthy without weight loss. When replacing another heartworm preventive product, ProHeart® 6 should be given before the last dose of the former product. ProHeart® 6 eliminates the larval and adult stages of *A. caninum* and *U. stenocephala* present at the time of treatment. However, persistent effectiveness has not been established for this indication. Re-infection with *A. caninum* and *U. stenocephala* may occur soon after a ProHeart® 6 treatment.

**Dose:** The recommended subcutaneous dose is 0.05 mL of the constituted suspension/kg body weight (0.0227 mL/Lb). This amount of suspension will provide 0.17 mg moxidectin/kg body weight (0.0773 mg/lb.). To ensure accurate dosing, calculate each dose based on the dog’s weight at the time of treatment. Do not over-grow puppies in anticipation of their expected adult weight. The following dosage chart may be used as a guide.

**Injection Technique:** The two-part sustained release product must be mixed at least 30 minutes prior to the intended time of use (see CONSTITUTION PROCEDURES for initial mixing instructions). Once constituted, swirl the bottle gently before every use to uniformly re-suspend the microspheres. Withdraw 0.05 mL of suspension/kg body weight into an appropriately sized syringe fitted with either a 18G or 20G hypodermic needle. Dose promptly after drawing into dosing syringe. If administration is delayed, gently roll the dosing syringe prior to injection to maintain a uniform suspension and accurate dosing. Using aseptic technique, inject the product subcutaneously in the left or right side of the neck (or any convenient, non-injection sensitive area). The location of each injection left or right side should be noted so that prior injection sites can be identified and the next injection can be administered on the opposite side.

**INFORMATION FOR DOG OWNERS**
Always provide Client Information Sheet and review with owners before administering ProHeart® 6. Owners should be advised of the potential for adverse drug reactions, including anaphylaxis, and be informed of the clinical signs associated with drug toxicity (see WARNINGS, PRECAUTIONS and ADVERSE REACTIONS sections). Owners should be advised to contact their veterinarian immediately if signs of toxicity are observed. In most reported cases with drug related adverse reactions have recovered when the signs are recognized and veterinary care is provided, if appropriate, is initiated.

**CONTRAINdications**
ProHeart® 6 is contraindicated in animals previously found to be hypersensitive to this drug.

**human WARNings**
Not for human use. Keep this and all drugs out of the reach of children.

**WARNINGS**
ProHeart® 6 should be administered with caution in dogs with pre-existing allergic disease, including food allergy, atopy, and flea allergy dermatitis. In some dogs, systemic reactions have resulted in liver disease and death. Anaphylactic and anaphylactic reactions should be treated immediately with the same measures used to treat hypersensitivity reactions to vaccines and other injectable products.

Owners should be given the Client Information Sheet for ProHeart® 6 to read before the drug is administered and should be advised to observe their dogs for potential drug toxicity described in the sheet. Do not administer ProHeart® 6 to dogs who are sick, debilitated, underweight or who have a history of weight loss.

**PRECautionS**
Caution should be used when administering ProHeart® 6 concurrently with vaccinations. Adverse reactions, including anaphylaxis, have been reported following the concomitant use of ProHeart® 6 and vaccinations (see WARNINGS). Prior to administration of ProHeart® 6, the health of the patient should be assessed by a thorough medical history, physical examination and diagnostic testing as indicated (see WARNINGS). ProHeart® 6 should not be used more frequently than every 6 months. The safety and effectiveness of ProHeart® 6 has not been evaluated in dogs less than 6 months of age. Caution should be used when administering ProHeart® 6 to heartworm positive dogs (see ADVERSE REACTIONS). Prior to administration of ProHeart® 6, dogs should be tested for existing heartworm infections. Infected dogs should be treated to remove adult heartworms. ProHeart® 6 is not effective against adult worms and, while the number of circulating microfilariae may decrease following treatment, ProHeart® 6 is not effective for microfilaricide.

**ADVERSE REACTIONS**
In field studies, the following adverse reactions were observed in dogs treated with ProHeart® 6: anaphylaxis, vomiting, diarrhea (with and without blood), listlessness, weight loss, seizures, injection site pruritus, and elevated body temperature. Dogs with clinically significant weight loss (>10%) were more likely to experience a severe adverse reaction. In a laboratory effectiveness study, dogs with 4-6 month-old heartworm infections experienced vomiting, lethargy and bloody diarrhea. These signs were more severe in the dogs with 4-month-old heartworm infections, including one dog that was recumbent and required supportive care, than in the dogs with 6-month-old infections.

**STORAGE INFORMATION**
Store the unconstituted product at or below 25°C (77°F). Do not expose to light for extended periods of time. After constitution, the product is stable for 8 weeks stored under refrigeration at 2°C to 8°C (36°F to 46°F).